Zidesamtinib

Zidesamtinib (NVL-520) is a potent, selective, orally active and brain-penetrant inhibitor of diverse ROS1 fusions and resistance mutations, with IC50s of 0.7 and 7.9 nM for wild-type ROS1 and ROS1 G2032R, respectively, and spares TRK inhibition. Zidesamtinib can be used for the research of cancer[1].

Product Specifications

CAS Number

[2739829-00-4]

Product Name Alternative

NVL-520; NUV-520

UNSPSC

12352005

Target

ROS Kinase

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/zidesamtinib.html

Purity

99.55

Solubility

DMSO : 50 mg/mL (ultrasonic; warming; heat to 65°C)

Smiles

CCN1C2=C(C=N1)CC3=NN(C)N=C3C4=CC=C(F)C=C4[C@H](OC5=C(N)N=CC2=C5)C

Molecular Formula

C22H22FN7O

Molecular Weight

419.45

References & Citations

[1]Drilon A, et, al. NVL-520 is a selective, TRK-sparing, and brain-penetrant inhibitor of ROS1 fusions and secondary resistance mutations. Cancer Discov. 2022 Dec 13; CD-22-0968.